Jill Bargonetti first attended a Hunter College class in utero. According to the breast cancer researcher and dancer, her mother credited the statistics class she took while pregnant in helping shape Bargonetti���s scientific mind. From that early exposure, Bargonetti would go on to win the national Presidential Early Career Award for Scientists and Engineers. In addition to the White House, City Hall and the NAACP recognized her contributions to the field.
Bargonetti���s research probes the biology of cancer mutations. She focuses on one of the deadliest kinds of breast cancer, called triple negative, and an associated protein called mutant p53.
She works with clinicians to. With her students, she prepares the next generation of researchers who will fight the deadly mutations.
���We have to catch people young to enable them to have these types of scientific careers,��� from her office at Hunter College, from which she can see the hospital where she was born. She went on to learn at Hunter as a child, adding ���I have to credit my inquisitive nature��� with going to Hunter College Elementary School during a time when it was a lab school.���
Although Bargonetti studied dance in college, science stayed close to her heart, and she graduated with a Biology major. At times she says she was ���embarrassed to be a scientist. I didn’t let people know I was studying science while I was a dancer and then also going to graduate school for my PhD.���
���I’m never quite satisfied. I’m always trying to do better,��� says the Hunter professor, who�� chaired the Molecular Cellular and Developmental program at the Graduate Center for over a decade. She now leads the Hunter College Program for Research and Mentoring Postbaccalureates.
Bargonetti���s research has drawn over her three decades at Hunter. The National Institutes of Health, National Science Foundation, American Cancer Society, and the Department of Defense have supported her work.
Her team has yet to find a reason for why the p53 gene and protein are so highly mutated in triple-negative breast cancer. They know this mutant p53 helps the cancer cells thrive and be more deadly.-Mutant p53 presents in the vast majority of breast, lung, and ovarian cancer cases. Bargonetti says p53 mutations are highly prevalent in triple-negative breast cancer –.
Black women have a roughly. Bargonetti says, ���Something is happening in African American women’s lifetime that is promoting these sorts of mutations and what that is, is unclear.���
Bargonetti says some things put on Black women might contribute to the cancer disparity – from different hair and skincare products to disproportionate stress.
Bargonetti says CUNYhas supported her scientific journey, but she has also benefitted from inter-institution research collaborations. With oncologist Olufunmilayo I. Olopade at the University of Chicago and Melissa B. Davis, a scientific director at Morehouse School of Medicine, Bargonetti found that could be treated with PARP inhibitors, a cancer drug. They also found with those inhibitors.
Like her mother, Dr. Bargonetti made Hunter part of her family���s story early. She brought her nursing son to her first interview for a teaching position. After 30 years, her students are now younger than her children.
Recently, Bargonetti launched a new curriculum to teach her students her own way of understanding cellular and molecular interactions – through dance. ���When we discuss choreography, we also talk about the connection and the bonds – hold that person’s hand, move in unison,��� says Bargonetti, who first studied African dance at Hunter.
���When people write about science, they use a lot of choreography terms, but not in choreography language,��� she says, ���They’re really quite similar.���
The group moves with vogueing arms and post-modern steps, set to scientific narration and bebop trumpet. Bargonetti leads the group in an interpretation of the DNA replication and transcription, processes that go wrong in organisms when they get cancer. This interconnected perspective has served the researcher as she moves towards making the mutant p53 protein something that can hopefully be treated with medicine.
���If we can discover a way to drug that mutant p53, we will have opened a door to curative – or at least amazing – treatments for so many difficult-to-treat cancers,��� says Bargonetti. Those treatments could help clinicians fight roughly 80% of triple-negative breast cancers, 90% of ovarian cancers, and 70% of lung cancers where mutant p53 is present.
���If my work can be part of what lends the way to druggable mutant p53, I will be so gratified,��� says Bargonetti as she lets out a bright, hopeful laugh.
